Top Markets
#1 Bedrock Bedrock +34.97%
#2 Naoris Protocol Naoris Protocol +26.67%
#3 IQ IQ +17.63%
#4 pippin pippin +17.29%
#5 Bitway Bitway +17.15%
#6 Irys Irys +15.35%
#7 peaq peaq +10.50%
#8 Chrema Coin Chrema Coin +10.12%
#9 XPLA XPLA +10.05%
#10 ETHGas ETHGas +8.06%
Coin of the day
Bedrock Bedrock
Settings
Language
ENGLISH
Currency
USD
Theme
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rank in Stocks #20441
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Share Price
$0.16328419
Market Cap
$204.14K
Change (1 day)
4.35%
Change (1 year)
102.45%
Country
GB
Trade Fusion Antibodies plc (FAB)

Category

Healthcare
Number of shares outstanding for Fusion Antibodies plc (FAB)
Number of shares outstanding as of September 2025: 113.21M
According to Fusion Antibodies plc latest financial reports and stock price the company's current number of shares outstanding is 113.21M. At the end of March 2024 the company had 55.56M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Fusion Antibodies plc (FAB) from 2013 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 113.21M 18.07%
2025 95.88M 72.58%
2024 55.56M 113.55%
2023 26.01M 0.27%
2022 25.95M 1.91%
2021 25.46M 15.24%
2020 22.09M 0.00%
2019 22.09M 37.07%
2018 16.12M -27.04%
2017 22.09M 0.00%
2016 22.09M 0.00%
2015 22.09M 0.00%
2014 22.09M 0.00%
2013 22.09M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 3,828.84%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 124.27%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -9.11%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M 67.83%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M -45.75%
NL